Pricing
Prices are indicative MRP and may vary by pharmacy. Trend compares against the last recorded price.
All price changes →Indications & Uses
Trisela is indicated for:
Pharmacology
Trilaciclib is a transient inhibitor of CDK 4 and 6. Hematopoietic stem and progenitor cells (HSPCs) in the bone marrow give rise to the circulating neutrophils, RBCs and platelets, and these cells need CDK4/6 activity to multiply.
Bone Marrow:
In healthy subjects, a single dose of Trilaciclib 96 or 192 mg/m2 (0.4 or 0.8 times the approved recommended dose) slowed the proliferation of CD45+/CD3+ lymphocytes, and the effect grew with the dose. After a single dose of 192 mg/m2 (0.8 times the approved recommended dose), the percentage of cells held in G1 went up in every bone marrow progenitor subset that was checked, and this lasted up to 32 hours after the infusion. The subsets were hematopoietic stem cell/multipotent progenitor, oligopotent progenitor, monocyte lineage, granulocyte lineage, erythroid lineage and megakaryocyte lineage. By 32 hours after the dose, the total bone marrow had partly recovered and the progenitor subsets had started to proliferate again. This temporary G1 arrest of the hematopoietic stem cells contributed to the myeloprotective effect of Trilaciclib.
Cardiac Electrophysiology:
Trilaciclib is associated with an increase in the QTc interval that depends on the dose and appears after a delay. The mechanism behind this delayed QT effect is unknown. At the clinical dose of 240 mg/m2, Trilaciclib did not have a clinically relevant effect on QTc (i.e., >10 msec). QTc prolongation was seen at higher doses.
Dosage Reference
Reference Information Only
Dosages shown are general references from official sources. Always consult your doctor or pharmacist for personalized dosing.
Detailed dosing reference is not available yet. Please follow your prescription and consult your pharmacist.
Side Effects
Trilaciclib can cause injection-site reactions, including phlebitis and thrombophlebitis. It can also cause acute drug hypersensitivity reactions, and ILD/pneumonitis.
Cautions & Contraindications
Warnings & Precautions
Injection-Site Reactions, Including Phlebitis and Thrombophlebitis Trilaciclib can cause injection-site reactions, including phlebitis and thrombophlebitis. In clinical trials these occurred in 56 (21%) of 272 patients receiving it, with Grade 2 adverse reactions (ARs) in 10% and Grade 3 in 0.4%. Onset came a median of 15 days after the start of treatment (range 1 to 542), and 1 day after the preceding dose (1 to 15). Median duration was 1 day (range 1 to 151 for the resolved cases). Of the 56 patients, 49 (88%) recovered, and 3 (1%) of the 272 patients had to stop treatment because of these reactions. Watch patients for signs and symptoms of injection-site reactions, phlebitis and thrombophlebitis, including infusion-site pain and erythema during the infusion. For mild (Grade 1) to moderate (Grade 2) reactions, flush the line or cannula with at least 20 mL of sterile 0.9% Sodium Chloride Injection, USP or 5% Dextrose Injection, USP after the infusion ends. For severe (Grade 3) or life-threatening (Grade 4) reactions, stop the infusion and permanently discontinue Trilaciclib. Acute Drug Hypersensitivity Reactions Acute drug hypersensitivity reactions, including facial edema and urticaria, can also occur with this medicine. In clinical trials they were seen in 16 (6%) of 272 patients, and 2% of these were Grade 2 reactions. One patient had a Grade 2 anaphylactic reaction 4 days after a dose. Epinephrine resolved it, and Trilaciclib was continued. Median onset was 77 days from the start of treatment (range 2 to 256) and 1 day from the preceding dose (range 1 to 28). Median duration was 6 days (range 1 to 69 for the resolved cases). In 12 (75%) of the 16 patients the reactions resolved. Monitor patients for signs and symptoms of acute drug hypersensitivity reactions, including facial, eye and tongue edema, urticaria, pruritus and anaphylactic reactions. For moderate (Grade 2) reactions, stop the infusion and hold Trilaciclib until the reaction recovers to Grade ≤1. For severe (Grade 3) or life-threatening (Grade 4) reactions, stop the infusion and permanently discontinue Trilaciclib. Interstitial Lung Disease/Pneumonitis Severe, life-threatening or fatal interstitial lung disease (ILD) and/or pneumonitis can occur in patients treated with cyclin-dependent kinases (CDK)4/6 inhibitors, the same drug class as Trilaciclib. In clinical trials, ILD/pneumonitis occurred in 1 (0.4%) of 272 patients receiving Trilaciclib. That reaction was Grade 3 and was reported 2 months after Trilaciclib was stopped, in a patient who was taking a confounding medicine. It did not resolve. Monitor patients for pulmonary symptoms that point to ILD/pneumonitis, such as cough, dyspnea and hypoxia. For recurrent moderate (Grade 2) ILD/pneumonitis, permanently discontinue Trilaciclib. For severe (Grade 3) or life-threatening (Grade 4) ILD/pneumonitis, permanently discontinue Trisela. Embryo-Fetal Toxicity Based on its mechanism of action, Trilaciclib can cause fetal harm when given to a pregnant woman. Females of reproductive potential should use an effective method of contraception during treatment and for at least 3 weeks after the final dose.
Contraindications
Trilaciclib must not be given to anyone who has had a serious hypersensitivity reaction to Trilaciclib before. These reactions have included anaphylaxis.
Pregnancy & Breastfeeding
Because of how Trilaciclib works, it can harm an unborn baby when given to a pregnant woman. There are no human or animal data on Trilaciclib that could show whether it raises the risk of major birth defects, miscarriage, or other problems for the mother or the baby. Pregnant women should be told about the possible risk to the baby. For the people who are given this medicine, the background risk of major birth defects and miscarriage is not known. Every pregnancy carries some background risk of birth defect, pregnancy loss, or other poor outcomes. In the general population of the United States, the background risk of major birth defects is 2% to 4%, and the risk of miscarriage is 15% to 20% of clinically recognized pregnancies.
Nothing is known about whether trilaciclib passes into human or animal milk, what it does to a breastfed child, or whether it affects milk production. Because breastfed children could have serious side effects, women who are breastfeeding should be advised not to breastfeed while taking Trilaciclib and for at least 3 weeks after the last dose.
⚠️ Talk to your doctor before taking any medicine during pregnancy or while breastfeeding.
Overdose
Too much Trilaciclib can cause drowsiness, disorientation and extrapyramidal reactions.
Anticholinergic drugs, antiparkinsonism drugs or antihistamine drugs with anticholinergic properties may help control the extrapyramidal reactions. The symptoms usually clear on their own, and they generally disappear within 24 hours.
⚠️ In an emergency call 999 or go to the nearest hospital emergency department.
Storage
Store Trilaciclib below 30°C, and keep it away from light and moisture. Keep it out of the reach of children.
Drug Interactions
Common questions about Trisela 300 mg
What is Trisela 300 mg Injection?
Trisela 300 mg Injection is a medicine that contains Trilaciclib. It is made by Beacon Pharmaceuticals PLC. It belongs to the Transient inhibitor group of medicines.
What is Trisela used for?
Trisela is used for: Cancer.
What are the side effects of Trisela?
Trilaciclib can cause injection-site reactions, including phlebitis and thrombophlebitis. It can also cause acute drug hypersensitivity reactions, and ILD/pneumonitis.
Can I take Trisela during pregnancy or while breastfeeding?
Because of how Trilaciclib works, it can harm an unborn baby when given to a pregnant woman. There are no human or animal data on Trilaciclib that could show whether it raises the risk of major birth defects, miscarriage, or other problems for the mother or the baby. Talk to your doctor before taking any medicine during pregnancy or while breastfeeding.
What happens if I take too much Trisela?
Too much Trilaciclib can cause drowsiness, disorientation and extrapyramidal reactions. Anticholinergic drugs, antiparkinsonism drugs or antihistamine drugs with anticholinergic properties may help control the extrapyramidal reactions. In an emergency call 999 or go to the nearest hospital emergency department.
How should I store Trisela?
Store Trilaciclib below 30°C, and keep it away from light and moisture. Keep it out of the reach of children.
Can I take other medicines with Trisela?
Some medicines can interact with Trilaciclib, for example: Cisplatin, Dofetilide. Tell your doctor or pharmacist about every medicine you take.
Do I need a prescription for Trisela?
Trisela is a prescription (Rx) medicine. Take it as your doctor advises.